Finding Description
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** See the deficiency cited at Event KJ9713.
Based on interview and record review, the facility failed to ensure staff maintained documentation of medication as provided on the medication administration record and treatment administration for two months for three of three sampled residents (Residents #11, #12 and #10). The census was 77.
Review of the facility's Medication Administration policy, revised on 6/26/24, showed:
-Purpose: Medications are administered by licensed nurses or other staff who are legally authorized to do so in this state, as ordered by the physician and in accordance with professional standards of practice in a manner to prevent contamination or infection. It is the policy of the facility to ensure the safe and effective administration of all medications by utilizing best practice guidelines;
-General medication administration process:
-Ensure that the six rights of medication administration are followed:
1. Right resident;
2. Right drug;
3. Right dosage;
4. Right route;
5. Right time;
6. Right documentation;
-Sign medication administration record (MAR) after administered. For those medications requiring vital signs, record the vital signs onto the MAR;
-Correct any discrepancies and report to nurse manager
1. Review of Resident #11's quarterly Minimum Data Set (MDS), a federally mandated assessment instrument completed by facility staff, dated 10/16/24, showed:
-No behaviors or rejection of care;
-Bladder and Bowel: Appliances -Indwelling catheter;
-Medications: High risk drug classes use and indication:
-Taking anti-psychotic, anti-coagulant (prevents or reduces blood clotting) and anti-depressant;
-Diagnoses included: Schizophrenia (a disorder that affects a persons ability to think, feel and behave clearly), abnormal weight loss, adult failure to thrive, gross hematuria (blood in urine), unspecified glaucoma (eye conditions which can cause blindness), hyperlipidemia (high levels of fat particles in the blood), acute cystitis with hematuria (bladder infection), high blood pressure, hereditary and idiopathic neuropathy (inherited nerve damage) chronic kidney disease, insomnia (sleep disorder), muscle weakness, anxiety disorder, chronic embolism and thrombosis of deep vein of right distal lower extremity (a condition where a blood clot forms in a deep vein) and diabetes.
Review of the resident's care plan dated 10/16/24, showed:
-Problem: Nine plus medications;
-Interventions: Administer medications as directed. See physicians order sheets (POS). Monitor for effectiveness, adverse side effects: Increased lethargy, decreased balance, change in appetite or weight, change in sleep and inform physician;
-Problem: Anti-coagulation therapy;
-Interventions: Administer medications as directed. Monitor for bleeding of nose or gums, bruising, pain or hematuria and notify physician;
-Problem: Diabetes;
-Interventions: Accu-checks (a blood glucose (sugar) monitoring system) per physician's order. Accu check every Wednesday morning;
-Problem: Alteration in urinary function related to supra-pubic catheter (a thin, flexible tube that drains urine from the bladder through a small incision in the lower abdomen) in use;
-Interventions: Provide catheter care every shift. Irrigate and change in-dwelling catheter per physician's orders;
-Empty catheter drainage bag one time a shift and as needed and document amount of output;
-Problem: Psychotropic medication use;
-Interventions: Administer anti-depressant and anti-psychotic medications per physician's orders. Monitor for effectiveness/adverse side effects.
Review of the resident's POS dated 10/1/24 through 10/31/24, showed:
-Tamsulosin HCL oral capsule (cap) 9.4 milligrams (mg). Give one cap by mouth in the morning related to retention of urine. Take at the same time every day after a meal;
-Turmeric oral cap, 500 mg. Give one cap by mouth, one time a day for nutritional supplement;
-Vitamin C oral tablet (tab) 100 mg. Give one tab by mouth one time a day to promote wound healing;
-Gabapentin oral cap (used to treat nerve pain), 500 mg. Give one cap by mouth three times a day related to neuropathy;
-Senna oral tab 8.6 mg. Give one tab by mouth two times a day for constipation;
-Citalopram hydrobromide oral tab (anti-depressant), 40 mg. Give one tab by month one time a day;
-Nystatin external cream 100000 unit/grams (gm). Apply to lower abdomen, topically (on the skin) two times a day for skin infection;
-Oxybutynin chloride oral tab 5 mg. Give one tab by mouth one time a day related to overactive bladder;
-Ferrous Sulfate oral tab 325 mg. Give one tab by mouth one time a day related to iron deficiency;
-Eliquis oral tab 2.5 mg. Give one tab two times a day related to chronic embolism and thrombosis;
-Atorvastatin calcium oral tab, 80 mg. Give one tab by mouth at bedtime related to hyperlipidemia;
-Trazodone HCL oral tab 50 mg. Give 0.5 tab by mouth at bedtime related anxiety disorder;
-Melatonin oral tab 3 mg. Give 1 tab at bedtime related to insomnia;
-Risperidone oral tab (anti-psychotic) 1 mg. Give one tab at bedtime;
-Straight catheter twice daily in A.M., before breakfast and at bedtime if not voiding on own;
-Latanoprost Opthlamic solution 0.005%. Instill one drop in both eyes at bedtime related to unspecified glaucoma;
-Oxycodone HCL tab 5 mg. Give one tab by mouth every six hours as needed for pain;
-Acetaminophen oral tab 325 mg. Give two tabs by mouth every four hours as needed for elevated temperature/pain. Not to exceed 4000 mg in 24 hours;
-Supra pubic catheter care with soap and water every shift;
-Accu-check every Wednesday.
Review of the resident's eMAR dated 10/1/24 through 10/31/24, showed:
-Atorvastatin Calcium oral tab: No documentation of administration 10/1 through 10/31/24;
-Citalopram Hydrobromide oral tab: No documentation of administration 10/1 through 10/31/24;
-Ferrous Sulfate tab: No documentation of administration 10/1 through 10/31/24;
-Melatonin oral tab: No documentation of administration 10/1 through 10/31/24;
-Oxybutynin tab: No documentation of administration 10/1 through 10/31/24;
-Risperidone oral tab: No documentation of administration 10/1 through 10/31/24;
-Tamsulosin cap: No documentation of administration 10/1 through 10/31/24;
-Oxycodone HCL oral tab: No documentation of administration 10/1 through 10/31/24;
-Turmeric oral caps: No documentation of administration 10/1 through 10/31/24;
-Anticoagulant medication: Monitor for discolored, black tarry stools, sudden severe headache, diarrhea, muscle/joint pain, lethargy, sudden changes in mental status, shortness of breath, and nosebleeds: X's recorded for 10/1 through 10/3. All boxes left blank after 10/3/24;
-Anti-psychotic medication: Monitor for dry mouth, constipation, blurred vision, disorientation/confusion, difficulty urinating, dark urine, low blood pressure, yellow skin, lethargy, drooling, tremors, disturbed gait, increased agitation, restlessness or involuntary movement of mouth and tongue: X's recorded for 10/1 through 10/3. All boxes left blank after 10/3/24;
-Eliquis oral tab: No documentation of administration 10/1 through 10/31/24;
-Nystatin external cream: No documentation of administration 10/1 through 10/31/24;
-Gabapentin oral caps: No documentation of administration 10/1 through 10/31/24;
-Acetaminophen oral tab: No documentation of administration 10/1 through 10/31/24;
-Oxycodone HCL oral tab: No documentation of administration 10/1 through 10/31/24.
Review of the resident's electronic Treatment Administration Record (eTAR) dated 10/1/24 through 10/31/24, showed:
-Latanoprost Ophthalmic solution: No documentation of administration 10/1 through 10/31/24;
-Vitamin C oral tab: No documentation of administration 10/1 through 10/31/24;
-Senna oral tablet: No documentation of administration 10/1 through 10/31/24;
-No documentation of catheter care noted on eTAR.
Review of the resident's 11/1/24 through 11/30/24, POS, showed:
-Tamsulosin HCL oral cap 9.4 mg. Give one cap by mouth in the morning; Take at the same time every day after a meal;
-Turmeric oral cap 500 mg. Give one cap by mouth, one time a day;
-Vitamin C oral cap 100 mg. Give one cap by mouth one time a day;
-Gabapentin oral cap 500 mg. Give one cap by mouth three times a day;
-Senna oral tab 8.6 mg. Give one tab by mouth two times a day;
-Citalopram hydrobromide oral tab 40 mg. Give one tab by mouth one time a day;
-Nystatin external cream 100000 gm. Apply to lower abdomen, topically two times a day;
-Oxybutynin chloride oral tab 5 mg. Give one tab by mouth one time a day;
-Ferrous Sulfate oral tab 325 mg. Give one tab by mouth one time a day;
-Eliquis oral tab 2.5 mg. Give one tab two times a day;
-Atorvastatin calcium oral tablet 80 mg. Give one tablet by mouth;
-Trazodone HCL oral tab 50 mg. Give 0.5 tab by mouth at bedtime;
-Melatonin oral tab 3 mg. Give 1 tab at bedtime related to insomnia;
-Risperidone oral tab 1 mg. Give one tab at bedtime;
-Straight catheter twice daily in A.M.;
-Latanoprost Ophthalmic solution, 0.005%. Instill one drop in both eyes at bedtime;
-Oxycodone HCL tab, 5 mg. Give one tab by mouth every six hours, as needed;
-Acetaminophen oral tab 325 mg. Give two tabs by mouth every four hours as needed;
-Accucheck. Check and record weekly on Wednesdays;
-Supra-pubic catheter. Care with soap and water every shift;
-Pain assessment checks every shift.
Review of the resident's eMARs, dated 11/1/24 through 11/30/24, showed:
-Atorvastatin calcium oral tab: No documentation of administration 11/1 through 11/20, 11/22 through 11/25 and 11/27;
-Citalopram tab: No documentation of administration 11/1 through 11/26/24;
-Ferrous Sulfate tab: No documentation of administration 11/1 through 11/26/24;
-Melatonin tab: No documentation of administration 11/1 through 11/20/24, 11/22 through 11/25 and 11/27;
-Oxybutynin tab: No documentation of administration 11/1 through 11/30/24;
-Risperidone tab: No documentation of administration 11/1 through 11/18/24, 11/20 through 11/25 and 11/27;
-Tamsulosin cap: No documentation of administration 11/1 through 11/18/24 and 11/20 through 11/25/24;
-Oxycodone HCL tab: No documentation of administration 11/1 through 11/20/24 and 11/22 through 11/25/24 and 11/27;
-Turmeric cap: No documentation of administration 11/1 through 11/25/24;
-Anticoagulant medication: Monitor for discolored, black tarry stools, sudden severe headache, diarrhea, muscle/joint pain, lethargy, sudden changes in mental status, shortness of breath, and nosebleeds: No documentation of assessments performed 11/1 through 11/20/24, 11/22, 11/24 , a 9 recorded for 11/21;
-Anti-psychotic medication: Monitor for dry mouth, constipation, blurred vision, disorientation/confusion, difficulty urinating, dark urine, low blood pressure, yellow skin, lethargy, drooling, tremors, disturbed gait, increased agitation, restlessness or involuntary movement of mouth and tongue: No documentation of assessments performed 11/1 through 11/20/24, 11/21 and 11/22 during the dayshift, 11/22 through 11/24 during the night shift, 11/25 during the dayshift, and 11/27 and 11/30 during the night shift;
-Eliquis tab: No documentation of administration 11/1 through 11/25/24;
-Nystatin external cream: No documentation of administration 11/1 through 11/18/24, 11/19 on the evening shift, 11/20 through 11/22, 11/23 through 11/25 on the day shift and 11/25;
-Gabapentin cap: No documentation of administration 11/1 through 11/30/24;
-Acetaminophen tab: No documentation of administration 11/1 through 11/30/24;
-Oxycodone HCL tab: No documentation of administration 11/1 through 11/30/24;
-No documentation of accuchecks performed 1/1 through 11/18/24.
Review of the resident's eTAR dated 11/1/24 through 11/30/24, showed:
-Latanoprost Ophthalmic solution: No documentation of administration 11/1 through 11/20/24 and 11/22 through 11/24/24;
-Vitamin C oral tab: No documentation of administration 11/1 through 11/20/24 and 11/22 through 11/24/24;
-Assess for pain every shift: No documentation of pain assessed 11/1 through 11/20/24, 11/22/24 and 11/22 through 11/24/24 on evening shift;
-Senna oral tab: No documentation of administration 11/1 through 11/20/24, 11/22 and 11/24/24 on day shift and 11/21 through 11/24/24 during evening shift;
-No documentation of catheter care noted on eTAR.
Review of the resident's POS dated 12/1/24 through 12/31/24, showed:
-Tamsulosin HCL oral cap 9.4 mg. Give one cap by mouth in the morning;
-Turmeric oral cap 500 mg. Give one cap by mouth, one time a day;
-Vitamin C oral tab 100 mg. Give one tab by mouth one time a day;
-Gabapentin oral cap 500 mg. Give one cap by mouth three times a day;
-Senna oral tab 8.6 mg. Give one tab by mouth two times a day;
-Citalopram hydrobromide oral tab 40 mg. Give one tab by mouth one time a day;
-Nystatin external cream 100000 gm. Apply to lower abdomen, topically two times a day;
-Oxybutynin chloride tab 5 mg. Give one tab by mouth one time a day;
-Ferrous Sulfate tab 325 mg. Give one tab by mouth one time a day;
-Eliquis tab 2.5 mg. Give one tab two times a day;
-Atorvastatin calcium tab 80 mg. Give one tab by mouth;
-Trazodone HCL tab 50 mg. Give 0.5 tab by mouth;
-Melatonin tab 3 mg. Give 1 tab by mouth at bedtime related to insomnia;
-Risperidone oral tab 1 mg. Give one tab at bedtime;
-Straight catheter twice daily in A.M;
-Latanoprost Ophthalmic solution, 0.005%. Instill one drop in both eyes;
-Oxycodone HCL tab, 5 mg. Give one tab by mouth every six hours, as needed;
-Accucheck. Check and record weekly on Wednesdays;
-Supra-pubic catheter. Care with soap and water every shift;
-Acetaminophen tab 325 mg. Give two tabs by mouth every four hours as needed.
Review of the resident's MAR dated 12/1/24 through 12/31/24, showed:
-Atorvastatin Calcium tab: No documentation of administration 12/6/24, 12/16 and 12/17/24;
-Melatonin tab: No documentation of administration 12/6/24, 12/16 and 12/17/24;
-Risperidone tab: No documentation of administration 12/6/24 and 12/16 and 12/17/24;
-Trazodone HCL tab: No documentation of administration 12/6/24 and 12/16 and 12/17/24;
-Eliquis oral tab: No documentation of administration 12/11/24 on evening shift and 12/17/24 on evening shift;
-Nystatin external cream: No documentation of administration 12/6 and 12/7/24 on evening shift and 12/17/24 on evening shift;
-Gabapentin cap: No documentation of administration 12/11/24 on afternoon and evening shift and 12/17/24 on evening shift;
-Acetaminophen tab: No documentation of administration 12/1 through 12/30/24;
-Oxycodone HCL tab: No documentation of administration 12/1 through 12/30/24.
Review of the resident's eTAR dated 12/1/24 through 12/30/24, showed:
-Latanoprost ophthalmic solution: No documentation of administration 12/9/24, 12/16/24 and 12/17/24;
-Vitamin C tab: No documentation of administration 12/6/24 and 12/12/24;
-Senna tab: No documentation of administration 12/6/24, and 12/8/24 on the evening shift and on 12/12/24;
-Assess for pain every shift: No documentation of assessments performed 12/1 through 12/9/24 on the night shift and 12/12/24 on the day shift;
-No documentation of accuchecks performed 12/1 through 12/18/24;
-No documentation of catheter care noted on eTARs.
2. Review of Resident #12's quarterly MDS dated [DATE], showed:
-No behaviors or rejection of care;
-Medications: High risk drug classes use and indication:
-Taking anti-psychotic, anti-anxiety and anti-depressant;
-Diagnoses included Alzheimer's disease, heart disease, senile degeneration of brain, high blood pressure and vitamin D deficiency.
Review of the resident's care plan dated 8/12/24, showed:
-Problem: Nine plus medications;
-Interventions: Administer medications as directed/See physician's order sheet;
-Problem: Aspirin therapy;
-Interventions: Administer medications as directed. Monitor for bleeding of nose or gums, bruising, pain or hematuria and alert physician;
-Problem: Potential for pain;
-Interventions: Administer as needed pain medications per physician's orders. Administer routine pain medications per physician's orders. Monitor for effectiveness of pain management and alert physician as needed. Pain assessment quarterly/see assessment in chart.
-Review of the resident's POS dated 10/1/24 through 10/31/24, showed:
-Pain assessment. Check and record every shift;
-Alendronate sodium (used to treat osteoporosis) 70 mg , take one tab by mouth weekly on Monday and at least half an hour prior to breakfast;
-Aspirin 81 mg tab (used to treat pain). Chew one tablet by mouth daily;
-Calcium 250 mg/vitamin D3 125 mg tab (supplement). Take one tab by mouth daily;
-Donepezil HCL 10 mg tab (used to treat senile degeneration of brain). Take 1 tab by mouth daily;
-Escitalopram 10 mg (used to treat depression). Take one tab by mouth daily;
-Ingrezza 40 mg (used to treat tardive dyskinesia). Take 1 cap by moth twice daily;
-Lisinopril 2.5 mg (used to treat high blood pressure). Take 1 tablet by mouth daily;
-Memantine HCL 1.25 mg (used to treat senile dementia). Take one cap by mouth monthly on the 3rd;
-Vitamin D2 (Ergocalciferol) 1.25 mg capsule. Take one cap by mouth on the third Wednesday of each month;
-Quetiapine 25 mg tab (used to treat schizophrenia). Half tab by mouth every evening;
-Mirtazapine 30 mg tab (used to treat depression). Take one tab by mouth at bedtime;
-Acetaminophen 325 mg tab. Take two tab by mouth every four hours as needed for pain;
-Hydrocortisone 1% cream (used for dermatitis). Apply topically (to skin) once daily;
-Lorazepam 0.5 mg tab (used to treat anxiety). Take ½ tab by mouth three times daily;
-Nizoral 1% shampoo. Apply topically twice weekly.
Review of the resident's eMAR, dated 10/1/24 through 10/31/24, showed:
-Alendronate Sodium: No documentation of administration 10/7/24, 10/14/24, 10/21/24 and 10/12/24;
-Aspirin 81 mg: No documentation of administration 10/1 through 10/31/24;
-Calcium-Vitamin D3: No documentation of administration 10/1 through 10/31/24;
-Donepezil HCL 10 mg: No documentation of administration 10/1 through 10/31/24;
-Ergocalciferol: No documentation of administration 10/1 through 10/31/24;
-Citalopram 10 mg (generic for Escitalopram): No documentation of administration 10/1 through 10/31/24;
-Ingrezza 40 mg: No documentation of administration 10/1 through 10/31/24;
-Lisinopril 2.5 mg: No documentation of administration 10/1 through 10/31/24;
-Quetiapine Furmarate 25 mg: No documentation of administration 10/1 through 10/31/24;
-Mirtazapine 30 mg: No documentation of administration 10/1 through 10/31/24;
-Lorazepam 0.5 mg (should this be 0.5?): No documentation administration 10/1 through 10/31/24;
-Acetaminophen 325 mg: No documentation of pain levels or administration of medication 10/1 through 10/31/24.
-Anti-anxiety medication: Monitor for drowsiness, slurred speech, dizziness, depressive/impulsive behavior:
No documentation of assessments performed 10/1 through 10/31/24;
-Antipsychotic medication: Monitor for dry mouth, constipation, blurred vision, orientation/confusion, dark urine, increased agitation or restlessness: No documentation of assessments performed 10/1 through 10/31/24.
Review of the resident's eTAR dated 10/1 through 10/31/24, showed Nizoral shampoo: No documentation of administration 10/1 through 10/31/24.
-Review of the resident's POS dated 11/1/24 through 11/30/24, showed:
-Pain assessment. Check and record every shift;
-Alendronate sodium 70 mg , take one tablet by mouth weekly on Monday and at least half an hour prior to breakfast;
-Aspirin 81 mg tab. Chew one tablet by mouth daily;
-Calcium 250 mg/vitamin D3 125 mg tab. Take one tab by mouth daily;
-Donepezil HCL 10 mg tab. Take 1 tab by mouth daily;
-Escitalopram 10 mg. Take one tab by mouth daily;
-Ingrezza 40 mg. Take 1 cap by mouth twice daily;
-Vitamin D2 1.25 mg. Take one cap by mouth month on the 3rd of each month;
-Lisinopril 2.5 mg. Take 1 tablet by mouth daily;
-Memantine HCL 28 mg. Take one cap by mouth once daily;
-Vitamin D2 1.25 mg cap. Take one cap by mouth on the third Wednesday of each month;
-Quetiapine 25 mg tab. Take 1/2 tab by mouth every evening;
-Mirtazapine 30 mg tab. Take one tab by mouth at bedtime;
-Acetaminophen 325 mg tab. Take two tab by mouth every four hours as needed;
-Hydrocortisone 1% cream. Apply topically once daily;
-Lorazepam 0.5 mg tab. Take ½ tab by mouth three times daily;
-Nizoral 1% shampoo. Apply topically twice weekly.
Review of the resident's eMAR, dated 11/1/24 through 11/30/24, showed:
-Alendronate Sodium: No documentation of administration 11/4/24, 11/11/24, 11/18/24 and 11/25/24;
-Aspirin 81 mg: No documentation of administration 11/1 through 11/3/24;
-Calcium-Vitamin D3: No documentation of administration 11/1 through 11/30/24;
-Donepezil HCL 10 mg: No documentation of administration 11/1 through 11/30/24;
-Ergocalciferol: No documentation of administration 11/1 through 11/30/24;
-Citalopram Oxylate 10 mg: No documentation of administration 11/1 through 11/30/24;
-Ingrezza 40 mg: No documentation of administration 11/1 through 11/30/24;
-Lisinopril 2.5 mg: No documentation of administration 11/1 through 11/30/24;
-Quetiapine Furmarate 25 mg: No documentation of administration 11/1 through 11/30/24;
-Mirtazapine 30 mg: No documentation of administration 11/1 through 11/30/24;
-Lorazepam 0.5 mg: No documentation of administration on 11/1 through 11/18/24 and on 11/19/24 through 11/30/24;
-Atorvastatin 40 mg: No documentation of administration 11/1 through 11/20/24 and 11/22 through 11/30/24;
-Acetaminophen 325 mg: No documentation of pain levels or administration of medication 11/1 through 11/30/24.
-Anti-anxiety medication: Monitor for drowsiness, slurred speech, dizziness, depressive/impulsive behavior:
No documentation of assessments performed 11/1 through 11/20/24 and 11/22 through 11/30/24;
-Antipsychotic medication: Monitor for dry mouth, constipation, blurred vision, orientation/confusion, dark urine, increased agitation or restlessness: No documentation of assessments performed 11/1 through 11/20/24 and 11/22 through 11/30/24.
Review of the resident's eTAR dated 11/1 through 11/30/24, showed Nizoral shampoo: No documentation of administration 11/1 through 11/30/24.
Review of the resident's POS dated 12/1 through 12/31/24, showed:
-Pain assessment. Check and record every shift;
-Alendronate sodium 70 mg, take one tab by mouth weekly on Monday and at least half an hour prior to breakfast;
-Aspirin 81 mg tab. Chew one tab by mouth daily;
-Calcium 250 mg/vitamin D3 125 mg tab. Take one tab by mouth daily;
-Donepezil HCL 10 mg tab. Take 1 tab by mouth daily;
-Escitalopram 10 mg. Take one tab by mouth daily;
-Ingrezza 40 mg. Take 1 cap by mouth twice daily;
-Memantine HCL 1.25 mg. Take one cap by mouth month on the 3rd;
-Lisinopril 2.5 mg. Take 1 tab by mouth daily;
-Memantine HCL 28 mg. Take one cap by mouth, once daily;
-Vitamin D2 1.25 mg cap. Take one cap by mouth on the third Wednesday of each month;
-Quetiapine 25 mg tab. Take 1/2 tab by mouth every evening;
-Mirtazapine 30 mg tab. Take one tab by mouth at bedtime;
-Acetaminophen 325 mg tab. Take two tab by mouth every four hours as needed;
-Hydrocortisone 1% cream. Apply topically once daily;
-Lorazepam 0.5 mg tab. Take ½ tab by mouth three times daily;
-Nizoral 1% shampoo. Apply topically twice weekly.
Review of the resident's MAR, dated 12/1/24 through 12/18/24, showed:
-Alendronate Sodium: No documentation of administration 12/2/24, 12/9/24 and 12/16/24;
-Aspirin 81 mg: No documentation of administration 12/1 through 12/18/24;
-Calcium-Vitamin D3: No documentation of administration 12/1 through 12/18/24;
-Donepezil HCL 10 mg: No documentation of administration 12/1 through 12/18/24;
-Ergocalciferol: No documentation of administration 12/1 through 12/18/24;
-Citalopram Oxylate 10 mg: No documentation of administration 12/1 through 12/18/24;
-Ingrezza 40 mg: No documentation of administration 12/1 through 12/18/24;
-Lisinopril 2.5 mg: No documentation of administration 12/1 through 12/18/24;
-Quetiapine Furmarate 25 mg: No documentation of administration 12/1 through 12/18/24;
-Mirtazapine 30 mg: No documentation of administration 12/1 through 12/18/24;
-Lorazepam .05 mg: No documentation of administration 12/1 through 12/18;
-Atorvastatin 40 mg: No documentation of administration of medication 12/1 through 12/18/24;
-Acetaminophen 325 mg: No documentation of pain levels or administration of medication 12/1 through 12/18/24.
-Anti-anxiety medication: Monitor for drowsiness, slurred speech, dizziness, depressive/impulsive behavior: No documentation of assessments performed 12/1 through 12/18/24;
-Antipsychotic medication: Monitor for dry mouth, constipation, blurred vision, orientation/confusion, dark urine, increased agitation or restlessness: No documentation of assessments performed 12/1 through 12/18/24;
-Assess for pain every shift: No documentation of assessment performed 12/1 through 12/18/24.
Review of the resident's TAR dated 12/1 through 12/18/24, showed Nizoral shampoo: No documentation of administration 12/1 through 12/18/24.
3. Review of Resident #10's quarterly MDS dated [DATE], showed:
-No behaviors or refusal of care;
-Medications: High risk drug classes: Use and indication -
Taking anti-psychotics and anti-depressant;
-Diagnoses of schizophrenia, bipolar disorder (a disorder associated with episodes of mood swings ranging from depressive lows to manic highs), EPS (a group of side effects that occur due to the use of certain medications), high blood pressure, disorder of thyroid, Gastro-Esophageal reflux disease (GERD - a digestive disease in which stomach acid or bile irritates the food pipe lining), other specified disorders of bone density and structure, muscle weakness and age related osteoporosis (a condition in which the bones become weak and brittle).
Review of the resident's care plan dated 9/13/24, showed:
-Problem: Nine plus medications;
-Interventions: Administer medications as directed. See the POS. Monitor for effectiveness, adverse side effects, lethargy, decreased balance, change in appetite/weight, change in sleep and inform physician;
-Problem: Potential for pain;
-Interventions: Administer as needed pain medications per physician's orders. Administer routine pain medications per physician's orders. Monitor for effectiveness of pain management and alert physician as needed. Pain assessment quarterly/see assessment in chart;
-Problem: Psychotropic medication use;
-Interventions: Administer anti-depressant and anti-psychotic medications per physician's orders. Monitor for effectiveness/adverse side effects.
Review of the resident's POS dated 10/1 through 10/31/24 showed:
-Atorvastatin Calcium 20 mg tab. Take one tab by mouth at bedtime;
-Trazodone 50 mg tab. Take 1/2 tab by mouth at bedtime;
-Acetaminophen 325 mg tab. Take two tabs by mouth every four hours as needed for pain;
-Pantoprazole Sodium Oral tab 20 mg. Give one tab by mouth one time a day related to GERD;
-Benztropine Mesylate 0.5 mg. Give two times a month for EPS;
-Diclofenac Sodium 75 mg. Give one tablet two times a day for pain;
-Fluticasone Propionate Nasal suspension 50 micrograms (mcg). One spray in each nostril two times a day related to allergic rhinitis;
-Risperidone oral tab, 2 mg. Give one tab two times a day for schizophrenia and bipolar disorder;
-Furosemide (treats fluid retention, Lasix) 40 mg tab. Take one tab by mouth once daily;
-Ingressa 40 mg cap. Take one cap by mouth once daily;
-Lisinopril 5 mg tab. Take one tab by mouth daily;
-Oxybutynin Chloride Expended Release (ER) tab 10 mg. Take one tab by mouth daily;
-Oxygen at 2 liters per nasal cannula (a device used to give additional oxygen through the nose) for shortness of breath. Verbally authorize with physician within 24 hours;
-Health shakes, three times daily with meals;
-Pain assessment, check and record every shift.
Review of the resident's eMAR dated 10/1 through 10/31/24, showed:
-Atorvastatin Calcium 20 mg: No documentation of administration 10/1 through 10/31/24;
-Ingrezza 40 mg cap: No documentation of administration 10/1 through 10/31/24;
-Lisinopril 5 mg tab: No documentation of administration 10/1 through 10/31/24;
-Oxybutynin tab ER 10 mg: No documentation of administration 10/1 through 10/31/24;
-Pantoprazole Sodium tab 20 mg: No documentation of administration 10/1 through 10/31/24;
-Trazodone HCL 50 mg: No documentation of administration 10/1 through 10/31/24;
-Benztropine Mesylate 0.5 mg: No documentation of administration 10/1 through 10/31/24;
-Risperidone oral tab 2 mg: No documentation of administration 10/1 through 10/31/24;
-Acetaminophen 325 mg as needed (PRN). No documentation of administration 10/1 through 10/31/24;
-Antipsychotic medication: Monitor for dry mouth, constipation, blurred vision, orientation/confusion, dark urine, increased agitation or restlessness: No documentation of assessments performed 10/1 through 10/31/24;
-Health shake, three times a day for nutritional supplement: No documentation of administration 10/1 through 10/31/24;.
Review of the resident's eTAR dated 10/1 through 10/31/24, showed:
-Fluticasone Propionate Nasal 50 mcg: No documentation of administration 10/1 through 10/31/24;
-Diclofenac Sodium 75 mg: No documentation of administration 10/1 through 10/31/24;
-Change and date oxygen tubing weekly on Sundays, every night shift every Sunday: No documentation tubing was changed and dated 10/6, 10/13, 10/20 or 10/27;
-Assess for pain every shift: No documentation of assessments performed 10/2 through 10/31/24.
Review of the resident's ePOS dated 11/1/24 through 11/30/24, showed:
-Atorvastatin Calcium 20 mg tab: Take one tab by mouth at bedtime;
-Trazodone 50 mg tab: Take 1/2 tab by mouth at bedtime;
-Acetaminophen 325 mg tab: Take two tabs by mouth every four hours;
-Pantoprazole Sodium Oral tab 20 mg: Give one tab by mouth one time a day;
-Benztropine Mesylate 0.5 mg: Give two times a month;
-Diclofenac Sodium 75 mg: Give one tablet two times a day;
-Fluticasone Propionate Nasal suspension 50 mcg, one spray in each nostril two times a day;
-Risperidone oral tab 2 mg: Give one tab by mouth, two times a day;
-Ingressa 40 mg cap: Take one cap by mouth once daily;
-Lisinopril 5 mg tab: Take one tab by mouth daily;
-Oxybutynin Chloride ER tab 10 mg: Take one tab by mouth daily;
-Antipsychotic medication: Monitor for dry mouth, constipation, blurred vision, orientation/confusion, dark urine, increased agitation or restlessness;
-Oxygen at 2 liters per nasal cannula for shortness of breath. Verbally authorize with physician within 24 hours;
-Health shakes, three times daily with meals;
-Pain assessment, check and record every shift.
Review of the resident's eMAR dated 11/1 through 11/30/24, showed:
-Atorvastatin Calcium 20 mg: No documentation of administration 11/1 through 11/30/24;
-Ingrezza 40 mg cap: No documentation of administration 11/1 through 11/30/24;
-Lisinopril 5 mg tab: No documentation of administration 11/1 through 11/30/24;
-Oxybutynin tab ER 10 mg: No documentation of administration 11/1 through 11/30/24;
-Pantoprazole Sodium tab 20 mg: No documentation of administration 11/1 through 11/30/24;
-Trazodone HCL 50 mg: No documentation of administration 11/1 through 11/3